Loading...
Printed on 6/29/2026
For informational purposes only. This is not medical advice.
The Montreal Cognitive Assessment (MoCA) is a widely used cognitive screening tool designed to detect mild cognitive impairment (MCI) and early dementia. It assesses multiple cognitive domains: visuospatial/executive function, naming, memory, attention, language, abstraction, delayed recall, and orientation. Total score ranges from 0–30, with ≥26 considered normal. A 1-point education correction is added for individuals with ≤12 years of education. The MoCA has higher sensitivity than the MMSE for detecting MCI and is recommended by many neurology and geriatric guidelines as the preferred screening tool.
Formula: Total score 0–30. Add 1 point if education ≤12 years. Normal ≥26.
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The MoCA assesses seven cognitive domains through standardized tasks. Visuospatial/executive function (5 points): trail making B-pattern connecting alternating numbers and letters, cube copy, and clock drawing with hands set to 11:10. Naming (3 points): identifying drawings of a lion, rhinoceros, and camel. Attention (6 points): forward and backward digit span, tapping on the letter A, and serial 7 subtractions. Language (3 points): repeating two complex sentences verbatim and generating words beginning with the letter F. Abstraction (2 points): explaining how two items are similar (train/bicycle; watch/ruler). Delayed recall (5 points): recalling 5 words learned earlier without cues. Orientation (6 points): correctly stating date, month, year, day of week, place, and city. Standardized administration materials are required.
After completing all seven domains, the raw scores are summed to produce a total between 0 and 30. One bonus point is added if the patient has 12 or fewer years of formal education, correcting for the known effect of lower education on cognitive test performance. This education-adjusted total is the score used for interpretation. The maximum possible adjusted score is 30 (the correction is capped at 30). Document whether the education adjustment was applied and the patient's years of education as part of the clinical record.
An adjusted score of 26 or above is considered normal. Scores of 18-25 suggest mild cognitive impairment (MCI), which requires further evaluation and clinical correlation. Scores of 10-17 indicate moderate cognitive impairment, and scores below 10 indicate severe impairment consistent with advanced dementia. A MoCA score below 26 is a positive screen — it does not diagnose dementia but indicates that further evaluation is warranted, including clinical history, neurological examination, laboratory workup, and neuroimaging.
General Practitioners
The MoCA is the recommended first-line cognitive screening tool when a patient or family member reports memory concerns. Its 90% sensitivity for MCI makes it far more reliable than the MMSE for detecting early cognitive decline before dementia develops.
Neurologists and Geriatricians
Memory clinics use the MoCA to quantify cognitive impairment severity at initial evaluation, guide the intensity of further neuropsychological workup, and stratify patients into MCI vs mild dementia categories for treatment eligibility and care planning.
Geriatricians and Occupational Therapists
MoCA scores below 18-20 are associated with significantly impaired driving simulator performance and increased real-world crash risk. The MoCA is used as part of formal driving fitness evaluations in many jurisdictions for older adults with cognitive concerns.
Anesthesiologists and Surgeons
Documenting a pre-operative MoCA baseline identifies patients at elevated risk for post-operative cognitive dysfunction (POCD) and delirium, enabling tailored anesthetic management and informed consent discussions about cognitive risks of surgery in older adults.
Neuropsychologists
Serial MoCA administration tracks the rate of cognitive decline in patients with established Alzheimer's disease or other dementias. A decline of 2 or more points per year suggests active progression; stability may reflect treatment response or slow-progression disease.
Geriatric Psychiatrists
Cholinesterase inhibitors and memantine have approved indications for specific dementia severity ranges. MoCA scores document cognitive severity and support insurance authorization and clinical guidelines for initiating or adjusting anti-dementia medications.
The Montreal Cognitive Assessment is dramatically more sensitive than the MMSE for detecting mild cognitive impairment. At the validated cutoff of 26, MoCA sensitivity for MCI is 90% compared to only 18% for the MMSE. This difference occurs because the MoCA includes more challenging executive function, attention, and memory tasks that reveal early-stage decline missed by the MMSE's simpler items. Always use the MoCA rather than MMSE when the clinical question involves possible MCI.
The MoCA includes drawing tasks (trail making, cube copy, clock drawing) and verbal fluency tasks that require the examiner to observe the patient. Standard MoCA cannot be administered by telephone. A validated telephone version (T-MoCA) exists that omits visual tasks and adjusts cutoffs, but it is not interchangeable with the standard MoCA. Always use the standard face-to-face version for clinical assessments and document the administration method.
Add 1 point to the raw MoCA score for patients with 12 or fewer years of formal education. This correction accounts for the systematically lower performance on cognitive tests in less-educated populations without neurodegenerative disease. The correction is capped at 30 — it should not push a score above 30. Failure to apply this correction will falsely classify many cognitively normal individuals with limited education as impaired.
A MoCA score of 18-25 with clinical correlation suggests mild cognitive impairment (MCI), not dementia. MCI represents cognitive decline greater than expected for age but with preserved functional independence in daily activities. Approximately 10-15% of MCI patients convert to dementia per year, making follow-up and risk factor management critical. Educate patients that MCI is not inevitable progression — some patients remain stable or even improve.
A MoCA score below 26 is a positive screen, not a diagnosis. Dementia diagnosis requires: documented cognitive decline from prior level, impairment in two or more cognitive domains, functional impairment in daily activities, and ruling out delirium. The evaluation also requires clinical history, collateral informant interview, neurological examination, laboratory workup (thyroid, B12, metabolic panel), and often neuroimaging. Never diagnose dementia based on MoCA alone.
Different dementia subtypes produce different MoCA profiles. Alzheimer's disease: prominent memory (delayed recall) impairment, gradual onset. Vascular dementia: executive function and attention impairment predominate, stepwise progression with focal neurological signs. Lewy body dementia: fluctuating cognition plus visual hallucinations plus parkinsonism — visuospatial tasks often severely impaired. Frontotemporal dementia: executive function and language affected; memory may be relatively spared initially.
Patients with higher education and more cognitively complex careers have greater cognitive reserve, meaning they may have substantial neurodegenerative pathology before MoCA scores fall below 26. A highly educated professor scoring 23 may have more underlying pathology than a less-educated individual scoring 20. Serial MoCA testing and comparison to the patient's personal estimated baseline is more informative than single-point cutoffs in high-reserve individuals.
The MoCA-Basic is a validated alternate version designed for populations with limited literacy or very low education. It uses simpler verbal instructions and omits tasks heavily dependent on reading and writing. For populations in developing countries or with very low educational attainment, the MoCA-Basic may be more appropriate than the standard version. Document which version was used in clinical records.
Donepezil, rivastigmine, and galantamine are FDA-approved cholinesterase inhibitors for mild-moderate Alzheimer's disease dementia. They provide modest but clinically meaningful improvement in cognitive and functional outcomes, with effect sizes equivalent to approximately 6-12 months of disease progression delay. Memantine is approved for moderate-severe Alzheimer's. Anti-amyloid therapies (lecanemab, donanemab) represent newer disease-modifying approaches for early Alzheimer's disease.
Patients who have been administered the MoCA before may score higher on repeat testing due to learning and memory of specific test items, particularly the 5-word recall task. Practice effects can inflate scores by 2-4 points, potentially masking true cognitive decline or falsely suggesting improvement. When repeated testing is required at short intervals (less than 6 months), consider using an alternate form of the MoCA or supplementing with other cognitive measures to distinguish true change from practice effect.
MoCA published by Nasreddine et al. (J Am Geriatr Soc 2005) from 277 patients. Sensitivity 90% and specificity 87% for MCI vs normal at threshold 26. Sensitivity 100% for Alzheimer's dementia. Compared to MMSE sensitivity for MCI of 18%. MoCA copyright: available free for clinical use from mocatest.org for healthcare providers. International validation in 100+ countries. MCI annual conversion to dementia: Petersen et al. (Arch Neurol 2001). NIA-AA Alzheimer's criteria: McKhann et al. (Alzheimers Dement 2011).
Your adjusted MoCA score (with education correction if applicable) indicates cognitive function across multiple domains. A score of 26 or above is considered normal. Scores of 18-25 suggest mild cognitive impairment (MCI), which may represent early neurodegenerative disease, vascular cognitive impairment, or other treatable causes of cognitive decline. Scores of 10-17 suggest moderate cognitive impairment consistent with dementia. Scores below 10 suggest severe cognitive impairment.
A low MoCA score is not a diagnosis — it is a screening result that warrants further evaluation. Many conditions can cause cognitive impairment, including depression, medication side effects, sleep apnea, thyroid dysfunction, vitamin B12 deficiency, and normal pressure hydrocephalus, some of which are reversible. A comprehensive evaluation including neuropsychological testing, laboratory workup, and neuroimaging may be appropriate.
Use the MoCA score interpreter when a Montreal Cognitive Assessment has been administered and you need to contextualize the result. The MoCA is recommended as a first-line cognitive screening tool for patients with subjective memory complaints, for older adults during routine health evaluations, and for patients with conditions associated with cognitive decline (stroke, Parkinson disease, heart failure, diabetes).
It is also used for serial monitoring of cognitive function over time — for example, tracking progression in patients with known MCI or assessing response to cholinesterase inhibitor therapy. A decline of 2 or more points on serial testing may be clinically meaningful, though practice effects can artificially inflate repeat scores.
The MoCA is a screening tool, not a diagnostic instrument. A score below 26 does not confirm dementia or MCI, and a score of 26 or above does not exclude it. The standard cutoff of 26 has high sensitivity but lower specificity, meaning some cognitively normal individuals will screen positive. Some experts have suggested that a cutoff of 23 may be more appropriate in certain populations to reduce false positives.
The MoCA is influenced by education, language, and cultural factors. The 1-point education correction for individuals with 12 or fewer years of education is a rough adjustment and may not fully account for educational disparities. Performance can also be affected by anxiety, fatigue, sensory impairments (hearing or vision), and the testing environment. The MoCA should not be used as a standalone tool for major clinical decisions such as driving fitness or capacity assessments without comprehensive neuropsychological evaluation.
For related assessments, see MMSE Score, CAM Delirium Screen and Clinical Frailty Scale.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Interpret Mini-Mental State Examination (MMSE) scores. The classic cognitive screening test for dementia, scoring 0–30.
OpenGeriatricsScreen for delirium using the CAM (Confusion Assessment Method). Gold standard with ~94% sensitivity and ~89% specificity. Requires acute onset + inattention, plus disorganized thinking or altered consciousness.
OpenGeriatricsAssess frailty using the Rockwood Clinical Frailty Scale (CFS 1–9): Very Fit to Terminally Ill. Used for hospice eligibility, prognostication, ICU triage, surgical risk stratification, and goals-of-care discussions.
OpenEmergencyCalculate the Glasgow Coma Scale score to assess level of consciousness. Used worldwide in emergency medicine and trauma assessment.
Open